Biognosys Next Generation Proteomics Services Seminar at ASMS2024

Accelerating Drug Discovery and Development with Biognosys’ Next-Generation Proteomics Services


Mass Spectrometry-Based Approaches to Targeted Protein Degradation
Drug Discovery and Development

Development of a Quantitative CSF LRRK2 Assay to Support Clinical Studies

Short Bio Eric Kuhn:

Eric is an Associate Director, Targeted Proteomics at Kymera Therapeutics. He is an expert with over 20+ years of experience deploying peptide quantitation assays using stable isotope-labeled standards and targeted mass spectrometry to quantify proteins. He has developed pre-enrichment strategies and automation in combination with these assays to verify biomarker discovery findings in ovarian cancer, breast cancer, rheumatoid arthritis, and cardiovascular disease while at Millennium Pharmaceuticals and The Broad Institute. Eric has a BS in Biochemistry from University of New Hampshire and currently continues the development and management of high sensitivity MS-based assays to monitor the pharmacodynamic effects of TPD degraders throughout the drug development pipeline across the portfolio at Kymera.

Short Bio Alan Shomo:

Alan is a Principal Associate Scientist in Biogen’s Fluid Biomarkers department. He is an experienced analytical chemist with expertise in LC/MS-based biomarker discovery and development. His current focus is developing targeted proteomics biomarker assays to support and de-risk drug development and clinical trials.

Development, intra-laboratory transfer, and automation of hybrid targeted mass spectrometry assays for clinical biomarker profiling

Deep, Reproducible, and High Throughput Plasma Proteomics with the P2 Plasma Enrichment System

Short Bio Luca Raess:

Luca is a Senior Scientist I in the Biognosys R&D department. He earned his Master’s Degree in Biotechnology from ETH Zürich. After completing his studies, Luca joined the Biognosys sample preparation team, where he mainly focuses on laboratory automation. His responsibilities encompass developing novel workflows and translating existing ones into fully automated proteomics workflows.

Short Bio Oliver Rinner:

Oliver is a co-founder and CEO of Biognosys. He led the company from a spin-off from ETH Zurich in 2008 to a market-leading inventor and provider of proteomics technology and solutions today. Oliver joined the group of proteomics pioneer Ruedi Aebersold at ETH in 2005, where he worked on the development of technologies for targeted and structural proteomics and contributed to the seminal papers and patents that laid the foundation of next-generation proteomics. 

Back to Resources overview


    Close banner

    New: Spectronaut® 19

    Unlock Your Data's True Story

    New: Spectronaut® 19

    Unlock Your Data's True Story

    Learn More